deltatrials
Not Yet Recruiting INTERVENTIONAL NCT07527013

Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke (RESCUE-BP)

Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke (RESCUE-BP)

Sponsor: Beijing Tiantan Hospital

Updated 2 times since 2026 Last updated: Apr 17, 2026 Started: Jun 1, 2026 Primary completion: Nov 30, 2027 Completion: Feb 29, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Ischaemic Stroke and Blood Pressure Management, this trial is actively recruiting participants. The trial is conducted by Beijing Tiantan Hospital and has accumulated 2 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Apr 16, 2026 – Apr 23, 2026 · 7 days · daily APIApr 23, 2026 – present · 4 months · daily APINot Yet Recruiting

Change History

2 versions recorded
  1. Apr 23, 2026 — Present [daily]

    Not Yet Recruiting

  2. Apr 16, 2026 — Apr 23, 2026 [daily]

    Not Yet Recruiting

    First recorded

Eligibility Summary

The RESCUE-BP is a multi-centered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. In patients with acute ischemic stroke who have undergone endovascular treatment and achieved successful recanalization, the evaluation will compare a stratified blood pressure management strategy based on the collateral circulation status with the guideline-recommended conventional blood pressure management strategy. Within each stratum, participants will be randomized in a 1:1 ratio to either the stratified blood pressure management strategy group or the guideline-recommended conventional blood pressure management group. The goal is to determine whether this can improve good functional outcomes at 90 days (90-day Modified Rankin Scale \[mRS\] score 0-2). The study consists of four visits including the day of randomization, 24±4 hours after randomization, 7±1 days after randomization and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function rating scale will be recorded during the program. The primary outcome is the modified Rankin Scale (mRS) score of 0 to 2 at 90±7 days after randomization. The primary safety outcome is the incidence of sICH within 24±4 hours after randomization.

Contact Information

Sponsor contact:
  • Beijing Tiantan Hospital
  • Central Hospital of Dalian University of Technology
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations